CTNS Genotype

Cystinosis is rare, but when it runs in a family or a child shows early signs, testing the CTNS (cystinosin) gene can settle the question for life. Mutations in this gene break a small transport protein that normally moves a molecule called cystine (the linked form of the amino acid cysteine) out of your cells' internal recycling compartments, letting it pile up and quietly injure the kidneys, eyes, thyroid, and other organs.

Knowing your CTNS genotype matters because early diagnosis changes outcomes. Children who start cystine-lowering medication early preserve kidney function and grow more normally, while a late diagnosis often means kidney failure in childhood. For adults with vague kidney or eye symptoms, this test can also identify a late-onset form that routine labs would never flag.

How CTNS Variants Cause Disease

The CTNS gene sits on chromosome 17 and encodes cystinosin, a protein that lives in the membrane of lysosomes (the small compartments inside your cells that break down and recycle worn-out molecules). Cystinosin's job is to pump cystine, the linked pair form of the sulfur-containing amino acid cysteine produced when lysosomes break down proteins, out of these compartments. When both copies of the gene are broken, cystine concentrates inside lysosomes, eventually forming crystals that damage tissues over years.

Cystinosis follows a recessive inheritance pattern. You need a faulty copy from each biological parent to develop the disease. People with only one faulty copy (carriers) are generally healthy but can pass the variant to their children. The severity of disease depends on how completely the variants disable cystinosin: total loss produces the severe infantile form, while partial function leads to milder juvenile or adult-onset disease.

Infantile Nephropathic Cystinosis

Most people with two severe CTNS variants present in the first year of life with a kidney problem called Fanconi syndrome, where the kidney loses salts, sugar, and small proteins into the urine. Without treatment, kidney function deteriorates and most untreated children reach end-stage kidney disease (the point at which dialysis or transplant is needed) in childhood.

An international study of 453 people followed over five decades found that earlier diagnosis and earlier start of cystine-depleting therapy were strongly tied to better linear growth and slower kidney decline. Delayed treatment and higher leukocyte cystine levels were the main risk factors for poor outcomes.

Juvenile and Late-Onset Forms

When at least one CTNS variant leaves some cystinosin function intact, disease can present in adolescence or adulthood. Juvenile patients may show up with protein in the urine, partial Fanconi syndrome, or only eye findings. A series of 14 patients with late-onset disease showed wide variation, with four reaching end-stage kidney disease 12 to 28 years after the first symptoms appeared. Genetic confirmation is often what clinches the diagnosis in these atypical cases.

Ocular Cystinosis

The mildest form mostly affects the eyes, with cystine crystals forming in the cornea and causing light sensitivity. Kidneys are largely spared. These individuals typically carry one severe and one mild CTNS variant, leaving enough cystinosin activity to protect the kidneys but not the cornea.

Beyond the Kidneys

Even with early treatment, cystinosin's absence affects organs beyond the kidneys. Reported findings include underactive thyroid, impaired testicular function in males (a study of 18 affected men found cryopreservation of sperm was an option in about 20 percent of cases), insulin-producing cell dysfunction, neurological and visual processing differences, and a pigmentation pattern with fair hair caused by altered melanin production in skin cells.

Variants by Ancestry

The specific CTNS changes that cause disease cluster by ancestry, which matters for what your test panel actually covers.

What this means for you: if your ancestry overlaps with one of these populations, ask whether the lab's panel specifically targets the founder variant for your background. A general sequencing run may miss large deletions unless it includes special analysis steps.

One-Time Result, Lifelong Implications

Your CTNS genotype does not change with time, diet, or treatment, so this test is performed once and the answer is permanent. The value comes from acting on it for life, not from retesting the gene. If you have two pathogenic variants, the ongoing monitoring that matters is for the downstream effects on organ function: kidney filtration, urine protein, electrolytes, growth (in children), thyroid hormones, and eye exams for corneal crystals. Standard cadence for these companion tests is at least annual, more often during active treatment changes or in the first decade after diagnosis.

Repeat genetic testing is only warranted if the original method may have missed a variant (for example, when a single-nucleotide panel did not include the common large deletion), or if confirmatory sequencing is needed before making major medical decisions.

When Genetic Results Can Mislead

• Variant panel coverage: the assay only detects the changes it is designed to find. A negative panel does not rule out a rare CTNS variant that the lab does not test for. Targeted panels generally include the common 57-kb deletion plus the most frequent point mutations, but exome and genome sequencing may miss large deletions without specific analysis.
• Ancestry-specific frequencies: a variant common in one population may be rare in another. The clinical meaning of a finding depends on the variant's known frequency and the ancestry of the person tested.
• Variants of uncertain significance: some CTNS changes are reported with unclear meaning. These require careful interpretation by a genetic counselor and may need functional studies or family testing to resolve.
• Clinical-grade versus consumer genetic results: direct-to-consumer reports of CTNS variants are not always validated to clinical standards, and a positive or negative finding should be confirmed with a clinical-grade test before guiding medical decisions.

What to Do With an Out-of-Pattern Result

If your result shows two pathogenic CTNS variants, the next step is confirming the diagnosis with a white blood cell cystine measurement and ordering a workup of organ function: kidney filtration (creatinine, cystatin C, eGFR), urine protein, serum electrolytes, thyroid hormones, and an eye exam looking for corneal crystals. Referral to a nephrologist with rare-disease experience and to a genetic counselor is appropriate. Cystine-lowering medication should be started as soon as the diagnosis is confirmed.

If you carry one pathogenic variant, no medical treatment is needed, but the result matters for family planning. Discuss carrier-screening options with your partner. If your result shows no pathogenic variants but symptoms strongly suggest cystinosis, ask about expanded sequencing methods that can find large deletions or rare variants the standard panel may have missed.